Stratia Interface review: a glossary result is not a finished-cream trial

The complete product declaration identifies Interface

The official Interface text calls the product a peptide cream and a moisturizer enriched with seven peptides. Its current declaration and gel-cream description identify the formula discussed here. The official Interface product record supplies the complete ingredient list used below.

The separate ingredient glossary is a narrower account of one named peptide. That distinction concerns the evidence available to this review, rather than the product’s quality. A short ingredient explanation cannot substitute for a complete finished-product declaration or establish that its reported findings came from Interface.

The copper entry belongs to a larger cream

The complete captured list names Copper Palmitoyl Heptapeptide-14 along with other peptides and non-peptide ingredients. The page separately names Heptapeptide-15 Palmitate in its targeting explanation. These details come from the Interface product record; they do not establish each constituent’s quantity or an independently measured delivery advantage.

The seven-peptide description remains a count, without equal-share arithmetic or a total copper fraction. The grade-and-purity guide separates those numerical and analytical questions from a named ingredient. A complete qualitative declaration can identify what the manufacturer lists while still leaving the quantitative formula unresolved.

Encapsulation describes the manufacturer’s technology story

Stratia explains encapsulation and a targeting companion peptide within its product narrative. The manufacturer description is useful for locating the claimed formulation approach. It is not this publication’s measurement of skin delivery, the encapsulated active fraction or comparative absorption.

The narrative also cannot establish which ingredient caused a finished-product appearance result. A technology explanation and a demonstrated outcome need their own supporting records. The Medik8 evidence review supplies a different technology-and-version question for further reading. Its complex percentage does not provide a missing specification for Interface.

The glossary has its own study claim

The separate Copper Palmitoyl Heptapeptide-14 glossary says one study showed a 33% decrease in wrinkle surface area and a 19% increase in skin elasticity after twenty-eight days. Those figures are attributed to the ingredient glossary, not to a finished-Interface trial identified by this review.

The short record does not name the study, population, tested concentration, preparation, comparison or complete methods. Its link to Interface establishes where the company says the ingredient appears, without closing the preparation-match question. The study-endpoint guide explains why a result needs the actual study setting and product identity attached.

The product link under “What it’s in” is meaningful as a manufacturer association between the named ingredient and Interface. It still does not say that the unnamed study tested this cream, its current formula or its complete base. A study of another preparation could not establish the same finished-product result solely through a shared ingredient name. Because the short glossary does not resolve the tested material, this review reports the claim as a glossary assertion and leaves its applicability to current Interface unverified. No missing study details are invented to strengthen that connection.

A reported change is not a constituent percentage

The glossary’s 33% and 19% concern its stated wrinkle-area and elasticity findings. They do not disclose copper loading in the cream, active purity or the magnitude of change any reader should expect. Both the glossary and the product declaration are needed to see the boundary between those questions.

FDA’s assessment vocabulary distinguishes kinds of outcome information and context-specific qualification. It does not identify the unnamed glossary study’s methods or qualify its endpoints. The framework supplies a reason to ask what was assessed, without inventing a rule that every study must carry FDA qualification.

Other percentages cannot fill the active-content gap

The Interface page refers to tiny percentages of glycolic and lactic components in its encapsulation vehicle. That wording concerns those named components, not a disclosed copper amount. Its packaging statements about recycled material and recyclability answer another question altogether. The captured product text does not make either category an active-concentration specification.

This review does not adopt the page’s compatibility or tolerance instructions as personal guidance. The relevant documentary point is narrower: a numerical phrase needs the correct subject. Packaging fractions, vehicle descriptions and study outcomes cannot be borrowed to supply an ingredient share that the examined record leaves unstated.

Related documents remain related, rather than equivalent

Interface’s product page establishes its declared cream identity and formulation narrative. The separate glossary records an ingredient-study assertion with missing preparation and method details. Reading the product record beside it is informative precisely because the unverified link to a current finished-cream trial stays visible.

For another name-and-number boundary, consult the NEOVA review, or return to the original source comparison. These are neutral reading routes. Neither related document nor another brand’s result can substitute for product-matched evidence, and no comparative clinical advantage follows from the two glossary percentages alone.